AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10665626
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (starting dose of 300 mg t.i.d., followed by standard dose titration for days 3 to 10)
Trial: 8889672
Drug: Intravenous buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous buprenorphine (1.2 mg)
Trial: 8889672
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine (4.0 mg)
Trial: 8889672
Drug: Buccal buprenorphine
RxNorm normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buccal buprenorphine (4.0 mg)
Trial: 22120044
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg cocoa flavanols
Trial: 22120044
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg cocoa flavanols
Trial: 12883399
Drug: Midazolam administered
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam administered extracorporeally (into the circuit)
Trial: 12883399
Drug: Midazolam administered
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam administered via central or peripheral access
Trial: 7651559
Drug: Domperidone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (3 x 20 mg daily)
Trial: 7651559
Drug: Ondansetron (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (3 x 8 mg daily)
Trial: 2759694
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein milk (3.1 g/100 ml)
Trial: 31743193
Drug: LIA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIA with 2.5 mL/kg of 0.2% ropivacaine
Trial: 28844191
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg amoxicillin plus 500 mg metronidazole, three times daily for 7 days during the first non-surgical phase (T1)
Trial: 28844191
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg amoxicillin plus 500 mg metronidazole, three times daily for 7 days during the second surgical phase (T2)
Trial: 28844191
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of Parvimonas micra before therapy
Trial: 22303705
Drug: Shenfu Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu Injection (SI) 200 mL (50 mL SI in 200 mL normal saline)
Trial: 22303705
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (200 mL normal saline)
Trial: 22303705
Drug: Shenfu Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu Injection (SI)
Trial: 16567436
Drug: Post-tamoxifen discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-tamoxifen discontinuation
Trial: 10912888
Drug: rhEPO (5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO (5,000 U, 3 times weekly for 4 weeks)
Trial: 8826493
Drug: Control: lumbar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: lumbar subcutaneous injection of 3 ml of 0.5% bupivacaine
Trial: 27930518
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of MSC transplantation and butylphthalide
Trial: 20066671
Drug: Escitalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram treatment for 5 weeks
Trial: 20066671
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment) for 1 week
Trial: 15881486
Drug: oxycodone/acetaminophen 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxycodone/acetaminophen 10 mg/650 mg
Trial: 15881486
Drug: codeine/acetaminophen 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: codeine/acetaminophen 60 mg/600 mg
Trial: 2183939
Drug: Sucralfate 2
RxNorm normalized name: sucralfate 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 2 gm twice daily
Trial: 377081
Drug: Ticrynafen 500
RxNorm normalized name: Ticrynafen
DrugBank: Tienilic acid (DB04831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticrynafen 500 mg once daily
Trial: 377081
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 or 100 mg
Trial: 25286684
Drug: Reinforcing Qi
RxNorm normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinforcing Qi and Activating Blood treatment (Yu‐Ping‐Feng capsules and Fu‐Fang‐Dan‐Shen tablets for 3 months)
Trial: 25286684
Drug: Reinforcing Qi
RxNorm normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinforcing Qi and Activating Blood treatment
Trial: 17202548
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive behavioral therapy (N=79)
Trial: 3595695
Drug: Amiodarone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (3 X 400 mg daily for 3 days) plus Methimazole (3 X 20 mg daily for 10 days)
Trial: 3595695
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus Methimazole (3 X 20 mg daily for 10 days)
Trial: 24757229
Drug: Automated predictive
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated predictive low glucose pump suspension system
Trial: 24757229
Drug: No pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pump suspension (control)
Trial: 24757229
Drug: Pump suspension
RxNorm normalized name: INTESTINAL PUMP SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pump suspension exceeding 2 hours
Trial: 24757229
Drug: Automated pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated pump suspension system
Trial: 15854139
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g intravenous ascorbic acid
Trial: 15328062
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH infusion (10 microg/kg, 6‐min square wave pulse)
Trial: 9496559
Drug: Octreotide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (50 mcg)
Trial: 3064919
Drug: Nimodipine 40
RxNorm normalized name: nimodipine 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 40 mg three times a day
Trial: 30242962
Drug: NYX-2925 (50-1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NYX-2925 (50-1200 mg single-ascending dose and 150-900 mg multiple-ascending dose)
Trial: 26580240
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg three times a day for 3 months
Trial: 25189490
Drug: ACE-inhibitor perindopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-inhibitor perindopril
Trial: 11561868
Drug: Oral proteolytic
RxNorm normalized name: PROTEOLYTIC ENZYME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral proteolytic enzyme preparation (enzyme tablets t.i.d. starting 3 days prior to radiation therapy and continuing up to 5 days after completion)
Trial: 3717115
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (lactulose or neomycin)
Trial: 28061543
Drug: GTDS (transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTDS (transdermal granisetron patch, 7 days)
Trial: 28061543
Drug: Oral granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral granisetron (2 mg/day, ≥2 days)
Trial: 28061543
Drug: GTDS and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTDS and Oral granisetron
Trial: 25499944
Drug: 220.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 220.5 mg of cis-palmitoleic acid once per day for 30 days
Trial: 25499944
Drug: Placebo (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1000 mg of medium chain triglycerides) once per day for 30 days
Trial: 18023435
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy for low sexual desire
Trial: 12878918
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Naltrexone and Acamprosate
Trial: 12878918
Drug: CBI alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBI alone without pills
Trial: 8952583
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg oral dose)
Trial: 7259838
Drug: Single alkylating
RxNorm normalized name: petroleum alkylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single alkylating agent chemotherapy
Trial: 7259838
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with cyclophosphamide, vincristine, and prednisone (CVP)
Trial: 7259838
Drug: Fractionated whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated whole body irradiation followed by low dose involved field irradiation
Trial: 31973700
Drug: Levobupivacaine/morphine (LM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine/morphine (LM)
Trial: 22142548
Drug: Post-paracentesis intravenous
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-paracentesis intravenous nutritional support with a balanced oral diet and a late-evening protein snack (Group A)
Trial: 22142548
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional protocol without parenteral support (Group B)
Trial: 19000028
Drug: DHEA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA therapy
Trial: 17208951
Drug: DHEA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA therapy in women with adrenal insufficiency
Trial: 8601041
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mannitol (50 g) and albumin (75 g) in the pump prime
Trial: 2632375
Drug: Antianxiety drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antianxiety drug
Trial: 4925514
Drug: Antimalarials
RxNorm normalized name: ANTIMALARIALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimalarials
Trial: 31980899
Drug: Body-oriented resilience
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body-oriented resilience therapy (BEATVIC)
Trial: 20537501
Drug: Glutamine group
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine group (l‐glutamine 0.4g/[kg d])
Trial: 18544001
Drug: Oral voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral voriconazole (200 mg single dose)
Trial: 18544001
Drug: Intravenous voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous voriconazole solubilized with SBECD (6 mg/kg twice daily on day 1, then 3 mg/kg twice daily from days 2-6, followed by 3 mg/kg on day 7)
Trial: 18544001
Drug: Intravenous voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous voriconazole solubilized with SBECD
Trial: 15752161
Drug: Desmopressin (DDAVP)
RxNorm normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin (DDAVP) infusion followed by platelet concentrates (PCs)
Trial: 1929272
Drug: Norfloxacin 200
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norfloxacin 200 mg daily
Trial: 1929272
Drug: Nitrofurantoin 50
RxNorm normalized name: nitrofurantoin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin 50 mg daily
Trial: 6800439
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin with sodium glycocholate
Trial: 17449497
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin
Trial: 24442886
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intravenous zoledronate
Trial: 22435747
Drug: G+P (Granulocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G+P (Granulocyte colony-stimulating factor with plerixafor)
Trial: 22435747
Drug: G-CSF (Granulocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (Granulocyte colony-stimulating factor)
Trial: 18981719
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta 10,000 IU thrice weekly and oral iron starting 10-15 days before treatment
Trial: 7501332
Drug: Vaginal PGE2
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vaginal PGE2 gel (2 mg)
Trial: 7501332
Drug: Vaginal PGE2
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vaginal PGE2 tablet (3 mg)
Trial: 2169703
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and cholecalciferol supplementation (1000 mg Ca/d and 1000 IU cholecalciferol/d)
Trial: 7214297
Drug: BCG immunotherapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG immunotherapy for periods of 9.4 +/- 1.7 months
Trial: 7214297
Drug: No BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No BCG immunotherapy (control group)
Trial: 28327694
Drug: Both SurfLink
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both SurfLink and control implants
Trial: 26318757
Drug: Goal-directed haemodynamic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed haemodynamic therapy using oesophageal Doppler during surgery
Trial: 24371255
Drug: A(H3N2) viruses
RxNorm normalized name: Haemagglutinin-strain A(H3N2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A(H3N2) viruses classified as homologous to the vaccine strains based on HA1 domain nucleic acid sequence
Trial: 24371255
Drug: A(H1N1) viruses
RxNorm normalized name: Haemagglutinin-strain A(H1N1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A(H1N1) viruses classified as homologous to the vaccine strains based on HA1 domain nucleic acid sequence
Trial: 20011757
Drug: Fluoride-containing dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride-containing dentifrice (NaF dentifrice) on a toothbrush for 60 s twice a day
Trial: 20011757
Drug: Unwaxed dental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unwaxed dental floss twice a day
Trial: 20011757
Drug: Waxed dental
RxNorm normalized name: Candelilla Wax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waxed dental floss twice a day in every interproximal space
Trial: 20011757
Drug: Drinking water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking water rinsing twice a day for 60 s
Trial: 17142825
Drug: 5 u
RxNorm normalized name: vitamin E 5 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 u of oxytocin as a bolus injection
Trial: 17142825
Drug: 5 u
RxNorm normalized name: vitamin E 5 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 u of oxytocin as an infusion over 5 min
Trial: 23759039
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (bolus and infusion)
Trial: 15107384
Drug: Rapid dosing
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid dosing regimen (10 mg over 30 seconds, repeated once after three minutes if pain score remained above three)
Trial: 15107384
Drug: Cautious dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cautious dosing regimen (5 mg over two minutes, repeated at three minute intervals if pain score remained above three to a maximum dose of 20 mg)
Trial: 15107384
Drug: Rapid dosing
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid dosing regimen
Trial: 15107384
Drug: Cautious dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cautious dosing regimen
Trial: 9630259
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (treatment for 4 months)
Trial: 9630259
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (4 months without treatment followed by 4 months of treatment)
Trial: 8001718
Drug: Maltitol solutions
RxNorm normalized name: Maltitol
DrugBank: Maltitol (DB16867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltitol solutions
Trial: 23821328
Drug: CarboRT (carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CarboRT (carboplatin 100 mg/m2)
Trial: 23821328
Drug: CisRT (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CisRT (cisplatin 40 mg/m2)
Trial: 14751362
Drug: Chemotherapy (estramustine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (estramustine 140 mg three times daily and etoposide 100 mg orally for 21 days)
Trial: 14751362
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of somatostatin analog (lanreotide 30 mg intramuscularly every 14 days) and dexamethasone (4 mg tapered to 1 mg)
Trial: 11105738
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of fluoxetine daily
Trial: 11599647
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of fluoxetine weekly
Trial: 15613168
Drug: Desipramine 75
RxNorm normalized name: desipramine 75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine 75 mg
Trial: 2974255
Drug: Atracurium administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium administered by fast-flowing crystalloid infusion in the antecubital fossa
Trial: 2974255
Drug: Atracurium administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium administered by winged needle in the antecubital fossa with flushing after thiopentone
Trial: 2974255
Drug: Atracurium administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium administered by winged needle in the antecubital fossa without flushing
Trial: 2974255
Drug: Atracurium administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium administered by winged needle in the dorsum of the hand without flushing
Trial: 2974255
Drug: Atracurium administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium administered by fast-flowing crystalloid infusion in the antecubital fossa (subgroup of patients with drug allergy)
Trial: 2974255
Drug: Atracurium administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium administered by fast-flowing crystalloid infusion in the antecubital fossa (subgroup of patients aged over 70 years)
Trial: 5328328
Drug: quinethazone 50
RxNorm normalized name: quinethazone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quinethazone 50 mg
Trial: 5328328
Drug: chlorothiazide 500
RxNorm normalized name: chlorothiazide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chlorothiazide 500 mg
Trial: 25264753
Drug: Sildenafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (20 mg)
Trial: 23450513
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg sildenafil, 3 times per day for 9 weeks
Trial: 16757158
Drug: Mizolastine 10
RxNorm normalized name: mizolastine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine 10 mg once a day for 5 days
Trial: 8440860
Drug: Multi-nutrient supplementation
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-nutrient supplementation with a 360-kcal high carbohydrate, low fat liquid supplement every day
Trial: 8440860
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high intensity progressive resistance training and multi-nutrient supplementation